Identification of tumor necrosis factor ␣ (TNF␣) as the key agent in inflammatory disorders led to new therapies specifically targeting TNF␣ and avoiding many side effects of earlier anti-inflammatory drugs. However, because of the wide spectrum of systems affected by TNF␣, drugs targeting TNF␣ have a potential risk of delaying wound healing, secondary infections, and cancer. Indeed, increased risks of tuberculosis and carcinogenesis have been reported as side effects after anti-TNF␣ therapy. TNF␣ regulates many processes (e.g. immune response, cell cycle, and apoptosis) through several signal transduction pathways that convey the TNF␣ signals to the nucleus. Hypothesizing that specific TNF␣-dependent pathways control specific processes and that inhibition of a specific pathway may yield even more precisely targeted therapies, we used oligonucleotide microarrays and parthenolide, an NF-B-specific inhibitor, to identify the NF-B-dependent set of the TNF␣-regulated genes in human epidermal keratinocytes. Expression of ϳ40% of all TNF␣-regulated genes depends on NF-B; 17% are regulated early (1-4 h post-treatment), and 23% are regulated late (24 -48 h). Cytokines and apoptosisrelated and cornification proteins belong to the "early" NF-B-dependent group, and antigen presentation proteins belong to the "late" group, whereas most cell cycle, RNA-processing, and metabolic enzymes are not NF-Bdependent. Therefore, inflammation, immunomodulation, apoptosis, and differentiation are on the NF-B pathway, and cell cycle, metabolism, and RNA processing are not. Most early genes contain consensus NF-B binding sites in their promoter DNA and are, presumably, directly regulated by NF-B, except, curiously, the cornification markers. Using siRNA silencing, we identified cFLIP/CFLAR as an essential NF-B-dependent antiapoptotic gene. The results confirm our hypothesis, suggesting that inhibiting a specific TNF␣-dependent signaling pathway may inhibit a specific TNF␣-regulated process, leaving others unaffected. This could lead to more specific anti-inflammatory agents that are both more effective and safer.